Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Nov 16;12(11):3395.
doi: 10.3390/cancers12113395.

Outcome After 68Ga-PSMA-11 versus Choline PET-Based Salvage Radiotherapy in Patients with Biochemical Recurrence of Prostate Cancer: A Matched-Pair Analysis

Nina-Sophie Schmidt Hegemann  1 , Paul Rogowski  1 , Chukwuka Eze  1 , Christian Schäfer  1 , Christian Stief  2 , Sebastian Lang  3 , Simon Spohn  3 , Rieke Steffens  1 , Minglun Li  1 , Christian Gratzke  4 , Wolfgang Schultze-Seemann  4 , Harun Ilhan  5 , Wolfgang Peter Fendler  6   7 , Peter Bartenstein  5 , Ute Ganswindt  8 , Alexander Buchner  2 , Anca-Ligia Grosu  3   9 , Claus Belka  1   10 , Philipp Tobias Meyer  11 , Simon Kirste  3 , Constantinos Zamboglou  3   9   12
Affiliations

Outcome After 68Ga-PSMA-11 versus Choline PET-Based Salvage Radiotherapy in Patients with Biochemical Recurrence of Prostate Cancer: A Matched-Pair Analysis

Nina-Sophie Schmidt Hegemann et al. Cancers (Basel). .

Abstract

The purpose of this analysis was primarily to analyze biochemical-recurrence free survival (BRFS) after positron emission tomography (PET)-guided salvage radiotherapy (sRT) in a large cohort, and to further compare BRFS after PSMA vs. choline PET/ computer tomography (CT)-based sRT. This retrospective analysis is based on 421 patients referred for PSMA or choline PET/CT after radical prostatectomy due to biochemically recurrent or persistent disease. BRFS (PSA: 0.2 ng/mL) was defined as the study endpoint. Cox regression analyses were performed to assess the impact of different clinical parameters on BRFS. Additionally, propensity score matching was performed to adjust patient cohorts (PSMA vs. choline PET/CT-based sRT). The median follow-up time was 30 months. BRFS at three years after sRT was 58%. In the multivariate analysis, only PSA before PET imaging and PSA before sRT were significantly associated with BRFS (p < 0.05). After propensity score matching, 272 patients were further analyzed; there was no significant difference in three-year BRFS between patients with PSMA PET-based vs. choline PET-based sRT (55% vs. 63%, p = 0.197). The present analysis confirmed the overall high BRFS rates after PET-based sRT and the strong prognostic effect of PSA level prior to sRT. PSMA PET-based sRT did not have superior BRFS rates when compared with choline PET-based sRT.

Keywords: PSMA PET/CT; choline PET/CT; matched-pairs analysis; prostate cancer; salvage radiotherapy.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Kaplan–Meier curve of biochemical-recurrence free survival (BRFS) for the entire cohort. Plotted symbols represent censored points. Error bars show 95% confidence interval.
Figure 2
Figure 2
Kaplan–Meier curve of BRFS PET-positive vs. PET-negative patients. Plotted symbols represent censored points. Error bars show 95% confidence interval. p value was obtained with log-rank test.
Figure 3
Figure 3
Kaplan–Meier curve of BRFS PSMA vs. choline PET in adjusted cohorts. Plotted symbols represent censored points. Error bars show 95% confidence interval. p value was obtained with log-rank test.
See this image and copyright information in PMC

References

    1. Han M., Partin A.W., Zahurak M., Piantadosi S., Epstein J.I., Walsh P.C. Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer. J. Urol. 2003;169:517–523. doi: 10.1016/S0022-5347(05)63946-8. - DOI - PubMed
    1. Shipley W.U., Seiferheld W., Lukka H.R., Major P.P., Heney N.M., Grignon D.J., Sartor O., Patel M.P., Bahary J.P., Zietman A.L., et al. Radiation with or without Antiandrogen Therapy in Recurrent Prostate Cancer. N. Engl. J. Med. 2017;376:417–428. doi: 10.1056/NEJMoa1607529. - DOI - PMC - PubMed
    1. Picchio M., Briganti A., Fanti S., Heidenreich A., Krause B.J., Messa C., Montorsi F., Reske S.N., Thalmann G.N. The role of choline positron emission tomography/computed tomography in the management of patients with prostate-specific antigen progression after radical treatment of prostate cancer. Eur. Urol. 2011;59:51–60. doi: 10.1016/j.eururo.2010.09.004. - DOI - PubMed
    1. Casamassima F., Masi L., Menichelli C., Bonucci I., Casamassima E., Lazzeri M., Gulisano M., Aterini S. Efficacy of eradicative radiotherapy for limited nodal metastases detected with choline PET scan in prostate cancer patients. Tumori. 2011;97:49–55. doi: 10.1177/030089161109700110. - DOI - PubMed
    1. Stefan A.K., Katharina S., Clemens K., Erik W., Matthias F.H., Sonja K., Ingmar S., Klaus H., Klaus K., Ali A.-O., et al. Clinical outcome of PSMA-guided radiotherapy for patients with oligorecurrent prostate cancer. Eur. J. Nucl. Med. Mol. Imaging. 2020 doi: 10.1007/s00259-020-04777-z. - DOI - PMC - PubMed